Skip to content

IOP Elevation Study

Effects of Elevated Intraocular Pressure on the Lamina Cribrosa

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03400137
Enrollment
150
Registered
2018-01-17
Start date
2018-03-07
Completion date
2024-05-08
Last updated
2023-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intraocular Pressure

Brief summary

The purpose of this study is to improve understanding of the pathophysiologic process that leads to the development of glaucamotous damage. The mechanism by which vision loss in glaucoma occurs is still unknown, but it is clear that increased intraocular pressure (IOP) is a major risk factor. It is also thought that the LC is a site of primary damage during pathogenesis of the disease. This prospective study with determine the in-vivo mechanical response to IOP modulation at the level of the ONH and LC.

Detailed description

The present study will briefly increase the pressure in eyes of living subjects and examine the effect of elevated intraocular pressure on optic nerve topography and position during pressure elevation using optical coherence tomography imaging of the posterior eye. Outcome measures will include measurements in microns based on these images quantifying the deformation of the lamina cribrosa.

Interventions

DIAGNOSTIC_TESTIncreasing of intraocular pressure (IC)

intraocular pressure will be increased using an ophthalmodynanometer

Sponsors

National Eye Institute (NEI)
CollaboratorNIH
NYU Langone Health
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

Healthy volunteers * No family history (first degree relative) of glaucoma. * No history of IOP \>22 mmHg. * Normal appearing optic discs and RNFL on dilated fundus examination. * Normal Swedish interactive thresholding algorithm (SITA) standard perimetry tests as defined by glaucoma hemifield test (GHT) within normal limits. Glaucoma suspects * Normal visual field as defined above. * Either IOP between 25 to 30 mmHg with central corneal thickness \< 550µm, or a difference ≥ 0.2 in cup to disc ratio between eyes. Glaucoma * Glaucomatous ONH abnormality: rim thinning, notching, undermining (excavation) or diffuse or localized RNFL defects that are characteristic of glaucoma. * Two consecutive abnormal SITA standard perimetry tests with GHT outside normal limits.

Exclusion criteria

* Media opacity (e.g. lens, vitreous, cornea). * Strabismus, nystagmus or a condition that would prevent fixation. * Diabetes with evidence of retinopathy. * Previous intraocular surgery or ocular trauma (with the exception of laser procedures and subjects that have undergone uneventful cataract surgery more than 6 months from enrollment date). * Neurological and non-glaucomatous causes for visual field damage. * Any intraocular non-glaucomatous ocular disorders.

Design outcomes

Primary

MeasureTime frameDescription
Assessment of the deformation of the lamina cribrosa in healthy eye in response to increasing intraocular pressure.10 MinutesOCT scanning will be obtained at baseline and with increased IOP. The IOP elevation will last no longer than two minutes, during which scans will be acquired by the imaging device.
Assessment of the deformation of the lamina cribrosa in glaucoma suspect, in response to increasing intraocular pressure.10 MinutesOCT scanning will be obtained at baseline and with increased IOP. The IOP elevation will last no longer than two minutes, during which scans will be acquired by the imaging device.
Assessment of the deformation of the lamina cribrosa in glaucomatous eyes in response to increasing intraocular pressure.10 MinutesOCT scanning will be obtained at baseline and with increased IOP. The IOP elevation will last no longer than two minutes, during which scans will be acquired by the imaging device.

Countries

United States

Contacts

Primary ContactJamika Singleton-Garvin
Jamika.Singleton-Garvin@nyulangone.org+1 929 455 5539

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026